198 results about "Bifidobacterium bifidum" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus polyactis composition for improving skin as well as a derivative and application of the lactobacillus polyactis composition. The composition comprises a bacterial strain, a pure culture or an inactivated bacterium body of bifidobacterium bifidum Bbifid-1 (CCTCC NO: M2023349), bifidobacterium adolescentis Badol-1 (CCTCC NO: M 20242593), phytobacterium plantarum Lplan-4 (CCTCC NO: M 20242594) and lactobacillus acidophilus (BA05). The invention further relates to a preparation method of the composition. The lactobacillus plantarum derivative composition prepared through treatment modes of splitting decomposition, extraction, fermentation and the like can be used as an active ingredient of a medicine or a cosmetic, has remarkable effects of resisting oxidation and bacteria, especially resisting inflammation and inhibiting skin lipid accumulation aiming at propionibacterium acnes and staphylococcus aureus, is beneficial to fading skin red and swollen, avoids hair follicle blockage, and has a good application prospect. The obvious effect on the acne is realized.

The invention discloses a livestock composite biological feed prepared from probiotics and a method thereof, and relates to the technical field of livestock feeds. The compound biological feed for the livestock and poultry is prepared from the following raw materials: lactobacillus plantarum BNCC138404, bacillus coagulans BNCC132591, bacillus velezensis BNCC352076, bifidobacterium bifidum BNCC186493, aspergillus niger BNCC147472, enterococcus faecalis BNCC186075, yarrowia lipolytica BNCC193899, nutrient substances, mineral trace elements, vitamins, amino acids and prebiotics. The compound biological feed for the livestock and poultry is prepared from the following raw materials: lactobacillus plantarum BNCC138404, bacillus coagulans BNCC132591, bacillus velezensis BNCC352076, bifidobacterium bifidum BNCC186493, aspergillus The compound biological feed fermented by adopting various probiotics can improve the antioxidant level of the broiler chicken, improve the health condition of intestinal tracts, increase the villus height and the villus-implicit ratio of the jejunum of the broiler chicken and reduce the occurrence of intestinal inflammation, so that the growth performance of the broiler chicken is promoted, and the immune performance of the body is improved.

The present invention relates to the technical field of microorganisms. Provided are a probiotic composition and a use thereof in the preparation of a product for preventing and / or treating anti-tumor treatment-related diarrhea and other health conditions. Active ingredients of the probiotic composition comprise Bifidobacterium bifidum, Enterococcus avium, Ligilactobacillus salivarius, Limosilactobacillus fermentum, and Parabacteroides distasonis. The probiotic composition has good safety, auto-aggregation capacity, antioxidant capacity, short-chain fatty acid production capacity, in-vitro cell adhesion capacity, capacity to inhibit multiple pathogenic bacteria, and capacity to treat anti-tumor treatment-related diarrhea, etc.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium longum subsp. Longum as well as a composition, a pharmaceutical composition, a culture, a food product or a dietary supplement containing the bifidobacterium longum subsp. Longum and application of the bifidobacterium longum subsp. Longum. The bifidobacterium longum is preserved in the Guangdong Microbial Culture Collection Center on January 21, 2025, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No.65836. The bifidobacterium longum subsp. Longum has relatively strong gastric acid and cholate tolerance and intestinal colonization capability; the bifidobacterium longum subsp. Longum can effectively utilize bifidobacterium bifidum to release monosaccharide or disaccharide outside cells for efficient proliferation, and the composition containing the bifidobacterium longum subsp. Longum, the bifidobacterium bifidum and breast milk oligosaccharide can release a large amount of short-chain fatty acid, so that the effects of maintaining the physiological function of an organism and improving the health of the organism are achieved.

The invention belongs to the technical field of microorganisms. The invention relates to a probiotic composition and application thereof in preparation of products for preventing and / or treating health conditions such as anti-tumor treatment related diarrhea. The probiotic composition comprises the following active ingredients: bifidobacterium bifidum, enterococcus faecalis, lactobacillus salivarius, lactobacillus fermentum mucus and parabacteroides didysonii. The probiotic composition has good safety, self-agglutination capability, oxidation resistance, short-chain fatty acid production capability, in-vitro cell adhesion capability, capability of inhibiting a plurality of pathogenic bacteria, capability of treating anti-tumor treatment related diarrhea and the like.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention provides a cobalt monatomic nano-enzyme system modified by phospholipid polyethylene glycol carboxyl. The cobalt monatomic nano-enzyme system comprises a cobalt monatomic nano-enzyme composite core and phospholipid polyethylene glycol carboxyl compounded on the surface of cobalt monatomic nano-enzyme, the cobalt monatomic nano-enzyme composite core comprises a cobalt monatomic nano-enzyme and ginsenoside loaded on the cobalt monatomic nano-enzyme. The invention also provides a bifidobacterium synergetic cobalt monatomic nano-enzyme system which is formed by combining cobalt monatomic nano-enzyme with ginsenoside Rb1 and further delivering the cobalt monatomic nano-enzyme and ginsenoside Rb1 through bifidobacterium bifidum for targeted therapy of enteritis. The combination of Co SA and Rb1 can enhance the anti-inflammatory efficacy by adjusting a key immune signal pathway, and bifidobacterium bifidum can ensure targeted delivery of microbiota and promote intestinal barrier repair. The synergistic three-component strategy integrating monatomic nano-enzyme antioxidation, natural drug immunoregulation and probiotic targeting is provided, and a promising treatment platform is provided for accurate intervention of IBD.

The present invention relates to novel lactic acid bacteria, Bifidobacterium bifidum P61 KCCM13367P, Lactobacillus paracasei P62 KCCM13368P, or a mixture thereof. The novel lactic acid bacteria and the mixture thereof of the present invention change the composition of intestinal microorganisms to inhibit the expression of sarcopenia markers (MuRF-1, MAFbx / Atrogin-1, etc.), increase muscle strength and muscle mass, and promote muscle formation, thereby alleviating sarcopenia. In addition, the present invention improves cognitive dysfunction by inhibiting behavior similar to cognitive dysfunction and regulating the expression of factors (BDNF, IL-10, etc.) associated with said dysfunction. In addition, the present invention has the effect of treating inflammation by reducing the expression of inflammatory markers (TNF-α, IL-6, IL-1ß, and MPO) and increasing the expression of an anti-inflammatory marker (IL-10).

The invention relates to the technical field of probiotics, in particular to a lactic acid bacteria strain composition with an effect of improving sleep quality and application. The lactic acid bacteria strain composition comprises a bifidobacterium breve BBr-28 strain, a bifidobacterium animalis subsp. Lactis PS23 strain, a bifidobacterium longum subsp. Infantis BR631 strain, a bifidobacterium bifidum BD-188 strain and a plant lactobacillus PQQ-1 strain. The lactic acid bacteria strain composition has the physiological activity function of improving the sleep quality, so that the lactic acid bacteria strain composition can be used for preparing food or composition for improving the sleep quality, and the problem of poor sleep quality is solved.

The invention belongs to the technical field of food processing, and particularly relates to fermented beef jerky and a preparation method thereof. The preparation method of the beef jerky comprises the following steps: (1) removing fascia and fat from fresh cattle hind leg meat, washing with clear water, and cutting into meat slices; (2) adding table salt, glucose, white granulated sugar and sodium nitrite into the sliced meat, uniformly mixing, adding a fermentation inoculant which comprises staphylococcus calcaratus, pediococcus acidilactici, bifidobacterium bifidum and Witzia ciliaris, and fermenting; and (3) after fermentation, drying and cooling to obtain the fermented beef jerky. Specific strains are selected to form a fermentation inoculant for fermentation, and the prepared fermented beef jerky is high in free amino acid and soluble peptide content, low in nitrite residual quantity, uniform red brown in color and slightly bright in surface, and belongs to high-quality beef jerky.

The invention provides a cordyceps militaris fermentation extract and application thereof in preservation of agaricus bisporus, and belongs to the technical field of deep processing of edible mushrooms and preservation of agricultural products. The preparation method of the cordyceps militaris fermentation extract comprises the following steps: (1) taking cordyceps militaris sporocarp, adding water, grinding, and performing enzymolysis by using cellulase and papain in sequence to obtain cordyceps militaris pulp; (2) adding glucose and waste beer yeast powder into the cordyceps militaris pulp, then inoculating lactobacillus paracasei and bifidobacterium bifidum, and fermenting; and (3) after fermentation is completed, carrying out ultrasonic crushing, centrifuging to remove thalli, and carrying out spray drying to obtain the cordyceps militaris fermentation extract. The method can effectively reduce the browning index and weight loss ratio of agaricus bisporus, can slow down the increase of malonaldehyde, reduces the activity of PPO enzyme, and prevents enzymatic browning caused by the synergistic effect of the PPO enzyme and peroxidase. The SOD enzyme activity in the agaricus bisporus can be kept, active oxygen in tissues can be removed, and the metabolic balance of the active oxygen can be maintained.

The invention discloses bifidobacterium bifidum and application thereof in improving asthma and histamine intolerance, and belongs to the technical field of marine microorganisms. The bifidobacterium bifidum NHNK-618 is preserved in the China Center for Type Culture Collection on August 9, 2024, and the preservation number of the bifidobacterium bifidum NHNK-618 is CCTCC (China Center for Type Culture Collection) NO: M20241761. The NHNK-618 has the functions of regulating asthma-related flora, agglutinating asthma-related pathogenic bacteria, reducing staphylococcus aureus enterotoxin, reducing bronchial histamine receptor activation, promoting bronchial barrier integrity, reducing airway remodeling and degrading histamine, and in addition, an NHNK-618 thallus biological membrane can improve the colonization capability on intestinal epithelial cells. The compound can be used for preparing products for improving asthma and histamine intolerance.

The invention provides application of a probiotic composition in preparation of a medicine for preventing and / or treating Alzheimer's disease, and belongs to the technical field of probiotic medical application. The probiotic composition disclosed by the invention is prepared from lactobacillus rhamnosus, bifidobacterium lactis and bifidobacterium bifidum. According to the probiotic composition disclosed by the invention, on the phylum level, the relative abundance of Verrucomicrobiota (verruca microflora phylum) is improved by the probiotic composition, and the relative abundance of the verrucomicrobiota (verruca microflora phylum) is improved by the probiotic composition; in the level of genus, the probiotic composition increases the relative abundance of the beneficial bacteria genus Akkermansia (Ackermania genus) and Bifidobacterium (Bifidobacterium genus), and in the level of genus Akkermania (Ackermania genus) and Bifidobacterium (Bifidobacterium genus); the behavioral cognition level can be remarkably improved, neuron injury is improved, and intestinal barrier injury is improved.

The invention relates to a ganoderma lucidum beverage and a making process thereof, and belongs to the technical field of drinks, the making process comprises the following steps: uniformly mixing lactobacillus acidophilus and bifidobacterium bifidum to obtain a mixed bacteria solution; inoculating the mixed bacterial liquid into a culture medium for culturing, and then mixing with a lucid ganoderma extract to obtain a lucid ganoderma active substance; packaging the lucid ganoderma active substance with maltodextrin and beta-lactoglobulin to obtain a lucid ganoderma encapsulated substance; and mixing the ganoderma lucidum encapsulation material, a sweetening agent, a thickening agent and water, homogenizing, sterilizing, cooling and aseptically filling to obtain the ganoderma lucidum beverage. According to the technical scheme, the two probiotics are mixed according to a certain volume ratio, intestinal flora balance can be effectively adjusted, proliferation of bad microorganisms in the intestinal tract can be inhibited, the probiotics and the ganoderma lucidum extract are jointly packaged in a microcapsule system formed by the maltodextrin and the beta-lactoglobulin, the stability of the microcapsule is improved, and the preparation process is simple and convenient. And the prepared ganoderma lucidum beverage has relatively good mouth feel and flavor.

Disclosed in the present invention is a probiotic. The probiotic comprises Parabacteroides distasonis with the microbial deposit number of CCTCC NO: M20222033, Limosilactobacillus fermentum with the microbial deposit number of CCTCC NO: M2023352, Lactobacillus salivarius with the microbial deposit number of CCTCC NO: M2023348, Enterococcus avium with the microbial deposit number of CCTCC NO: M2023350, and Bifidobacterium bifidum with the microbial deposit number of CCTCC NO: M2023349. The probiotic has good safety, has antioxidant activity, can inhibit pathogenic bacteria, can alleviate colon injury, can inhibit inflammation, and can alleviate diarrhea caused by chemotherapeutic drugs.

The invention belongs to the field of biological medicine, and particularly relates to bifidobacterium bifidum and application of the bifidobacterium bifidum in eye health products, and the bifidobacterium bifidum BB00 has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.34389. The invention further discloses a preparation method of the bifidobacterium bifidum. The bifidobacterium bifidum BB00 can improve clinical symptoms of xerophthalmia, increase tear secretion amount, prolong tear film rupture time, reduce ocular surface disease indexes, relieve corneal epithelium injury, adjust the opening degree of palpebral fissure, adjust intestinal flora composition, improve flora diversity and inhibit growth of intestinal pathogenic bacteria. The bifidobacterium bifidum BB00 not only provides an innovative solution for a clinical pain point of xerophthalmia and realizes synergistic intervention of intestinal regulation and eye health, but also has scientific innovation, clinical effectiveness and industrialization potential, and has important value for application of bacteria and fungicide in the field of biological medicine and treatment of ocular surface-intestinal tract related diseases.

The invention provides bifidobacterium bifidum and application thereof, and relates to the technical field of microorganisms. The invention provides Bifidobacterium bifidum NKU FB3-13, which is preserved in the Guangdong Microbial Culture Collection Center, the preservation number of which is GDMCC No: 64747, and the preservation number of which is GDMCC No: 64747. The invention also provides a preparation method of the Bifidobacterium bifidum NKU FB3-13. The strain has good acid resistance and can well adapt to the stomach environment; the strain can effectively reduce the colonization number of helicobacter pylori on gastric epithelium, can greatly reduce the colonization number of helicobacter pylori in animal experiments, relieves inflammation caused by helicobacter pylori infection, and reduces stomach intestinal metaplasia. The preparation method has a wide application prospect in the fields of clinical prevention, treatment and alleviation of diseases related to helicobacter pylori infection, gastrointestinal health-care food and the like.

The invention discloses a beta-galactosidase mutant derived from bifidobacterium bifidum and application thereof, and belongs to the technical field of enzyme engineering. The invention aims to improve the GOS synthesis yield and shorten the treatment time. The invention provides a beta-galactosidase mutant derived from bifidobacterium, and the mutant is obtained by mutating a 531 site, a 682 site, a 747 site or a 710 site by taking SEQ ID No.1 as a starting sequence. The glucoside conversion rate of the mutant W710F after reacting in a 350g / L lactose system for 5 hours reaches 45.90%, and is increased by 53.87% compared with that of a wild type. The beta-galactosidase mutant has the excellent properties of high catalytic efficiency and high yield of galactooligosaccharide, the cost of prebiotics is reduced, the conversion efficiency of producing galactooligosaccharide by using the beta-galactosidase mutant is improved, and the beta-galactosidase mutant has great industrial production and application potential and economic value.

The invention relates to application of lactobacillus helveticus HH-LPH17 in preparation of medicine for assisting in relieving inflammatory bowel diseases and relates to the technical field of probiotic compositions.The probiotic composition for treating the inflammatory bowel diseases comprises, by weight, 10 parts to 80 parts of lactobacillus johnsonii LBJ 456, 10 parts to 60 parts of lactobacillus helveticus HH-LPH17, 10 parts to 60 parts of lactobacillus acidophilus HH-LA26 and 10 parts to 60 parts of bifidobacterium longum HH-BL18. The composition comprises the following components in parts by weight: 10-60 parts of bifidobacterium bifidum HH-BB27 and 10-60 parts of bifidobacterium longum subspecies infantis HH-BI27. According to the probiotic composition for treating the inflammatory bowel disease, probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating the inflammatory bowel disease is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of the inflammatory bowel disease.

The invention discloses an agkistrodon halys peptide composite probiotic solid beverage and a preparation method of the agkistrodon halys peptide composite probiotic solid beverage. Comprising the following raw materials in parts by weight: 12 to 17 parts of ginseng oligopeptide powder, 12 to 17 parts of soybean oligopeptide powder, 5 to 10 parts of agkistrodon halys peptide powder, 10 to 15 parts of ganoderan, 15 to 20 parts of fructo-oligosaccharide, 15 to 20 parts of glucose, 8 to 12 parts of cranberry powder, 0.5 to 1.5 parts of anhydrous citric acid, 5 to 10 parts of bifidobacterium bifidum BGN4, 7 to 13 parts of gamma-aminobutyric acid, 5 to 10 parts of yeast beta-glucan and 0.04 to 0.07 part of vitamin E. According to the solid beverage, various active peptides such as the agkistrodon halys peptide, the ginseng oligopeptide and the soybean oligopeptide are compounded with the probiotics and the dietary fibers, the bioavailability of all the components is improved, absorption of peptide substances can be promoted through the activity of the probiotics, and meanwhile the immunity of the organism can be remarkably enhanced through the synergistic effect of various functional components.

The invention discloses a Bifidobacterium bifidum CCFM1424 capable of relieving senescence and an application of the Bifidobacterium bifidum CCFM1424, and belongs to the technical field of microorganisms. The bifidobacterium bifidum CCFM1424 disclosed by the invention can be used for effectively relieving cognitive defects of aged mice, improving the oxidation resistance (SOD, CAT, MDA and GSH-Px) of the brain and the liver, reducing the levels of proinflammatory factors TNF-alpha, IL-1beta and IL-6 in serum and relieving colitis. In addition, the intervention of the bifidobacterium bifidum CCFM1424 can maintain muscle health, and can improve the change of intestinal flora and intestinal metabolites related to aging. According to the bifidobacterium bifidum, the application range of the bifidobacterium bifidum as probiotics is expanded, and the bifidobacterium bifidum has a huge application prospect in the aspect of relieving senescence.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention relates to the technical field of medicinal and edible beverages, and discloses a formula and a preparation method of a ginseng probiotic fermented beverage. The ginseng probiotic fermented beverage is prepared from ginseng, fructus lycii, rhizoma polygonati, poria cocos, fructus crataegi, honey and a compound probiotic group. The beverage comprises the following raw materials in parts by weight: 5-15 parts of ginseng; 3-8 parts of fructus lycii; 2-5 parts of rhizoma polygonati; 1-3 parts of poria cocos; 3-6 parts of hawthorn; 5-10 parts of honey; the viable count of the composite probiotic group is (1-3) * 10 < 9 > CFU / mL; according to the preparation method, the medicinal and edible raw materials are subjected to enzymolysis and three-stage temperature-controlled fermentation, so that the release rate and the stability of active ingredients such as polysaccharide and saponin are improved; through synergistic interaction of lactobacillus plantarum, lactobacillus acidophilus and bifidobacterium bifidum in a ratio of 2: 1: 1, intestinal flora regulation and immune enhancement functions are enhanced; in addition, three-stage temperature control fermentation is combined with micro-aerobic regulation and control, a flora metabolism path is optimized, micromolecular active substances are enriched, thalli and macromolecular impurities are removed through a centrifugal combined ultrafiltration process, and the purity and the absorption rate of the active ingredients can be improved.

The invention discloses bifidobacterium bifidum and application of the bifidobacterium bifidum in relieving ovalbumin-induced food allergy, and belongs to the technical field of microorganisms. According to the invention, a strain of bifidobacterium bifidum CCFM1063 is screened out, and the bifidobacterium bifidum CCFM1063 has the effects of relieving weight loss and allergic symptoms of mice caused by OVA; according to the present invention, with the application of the loratadine, the high mMCP-1 level caused by OVA can be significantly reduced, the IgE level can be reduced, the mRNA level of the jejunum allergy related cytokines such as TSLP, IL-4 and IL-33 can be significantly reduced, and the partial effect is superior to the loratadine; when the bifidobacterium bifidum CCFM1063 is combined with breast milk oligosaccharide 3 '-SL, the bifidobacterium bifidum CCFM1063 has a synergistic effect on improving food allergy symptoms, and the effect of the bifidobacterium bifidum CCFM1063 is obviously superior to that of a single strain.

The invention discloses natto oligopeptide capable of relieving formation of arterial plaques and a preparation method and application thereof, belongs to the field of active peptide preparation, aims to solve the problem of obtaining natto or oligopeptide thereof capable of relieving formation of atherosclerotic plaques, and is characterized in that soybeans are soaked, sterilized, inoculated with compound bacteria, fermented at constant temperature and subjected to after-ripening to obtain natto, the volume ratio of the bacillus natto to the lactobacillus plantarum to the bifidobacterium bifidum in the compound bacteria is 1: (0.3-0.5): (0.1-0.3); compound protease is added into the aqueous solution of the freeze-dried natto powder for hydrolysis, centrifugation and filtration, components below 30000 Da are intercepted to obtain the natto oligopeptide, the ratio of chymotrypsin to papain in the compound protease is (1-3): 1, and the natto oligopeptide has the effects that the content of nattokinase in natto is higher, the protein level is also improved, and the natto oligopeptide can be used for preparing the natto oligopeptide. The nattokinase activity is well reserved in hydrolysis, the effect of promoting macrophage autophagy is achieved, and atherosclerotic plaque formation can be relieved.

The present invention discloses a Bifidobacterium bifidum strain and its application in adjuvant tumor therapy. The strain is named B.bifidum Zhang2021, which was deposited in the China Center for Type Culture Collection on September 5, 2022, with a deposit number of CCTCC M 20221374. It is identified as a newly discovered Bifidobacterium bifidum strain, and animal experiments have confirmed that the Bifidobacterium bifidum strain can effectively enhance the therapeutic effect of the immune checkpoint inhibitor PD-1 monoclonal antibody. The newly discovered Bifidobacterium bifidum strain in the present invention can be used to prepare biological preparations or drugs for human immunoregulation or tumor immunoadjuvant therapy, with diverse dosage forms and no toxic side effects, and has good application prospects.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium bifidum NKUFB3-12 and a composition thereof in preparation of products for relieving allergic diseases and / or regulating intestinal flora caused by allergy. The preservation number of the bifidobacterium bifidum NKUFB3-12 is GDMCC (China General Microbiological Culture Collection Center) No. 64013. The bifidobacterium bifidum NKUFB3-12 disclosed by the invention has excellent functional characteristics of relieving allergic diseases and regulating allergic intestinal flora, and also has excellent probiotic characteristics of acid resistance, cholate resistance and oxidation resistance, and the strain is safe and has no adverse side effect after being taken. The invention provides a composition. The composition comprises bifidobacterium bifidum NKUFB3-12 and 2 '-fucosyllactose (2'-FL), and the NKUFB3-12 is compounded with the 2 '-FL to show an effective inhibition effect on the imbalance of allergic immune response.

The present invention refers to a composition comprising or consisting of, a mixture of at least one probiotic strain belonging to the Lacticaseibacillus rhamnosus species, at least one probiotic strain belonging to the Bifidobacterium bifidum species, and at least one probiotic strain belonging to the Bifidobacterium longum subsp infantis species and the its use for the prevention or treatment of obesity and metabolic syndrome, as well as to pharmaceutical compositions and kits comprising the composition, to a composition for oral use comprising at least one probiotic strain and policosanols.

The invention provides ginseng freeze-dried powder capable of resisting oxidation, improving immunity and inhibiting cancer cell diffusion and a preparation method of the ginseng freeze-dried powder, and belongs to the technical field of ginseng processing. According to the ginseng freeze-dried powder researched and developed by the invention, three traditional Chinese medicinal materials including ginseng, lucid ganoderma and radix ophiopogonis are selected, the performance is improved through synergistic fermentation of bifidobacterium bifidum CICC-6168 and lactobacillus helveticus CICC-6273, then the ginseng freeze-dried powder is prepared by utilizing a vacuum freeze-drying technology, and the prepared product has the effects of resisting oxidation, improving immunity, inhibiting cancer cell diffusion and reducing uric acid.

The invention belongs to the technical field of microorganisms, and particularly discloses bifidobacterium bifidum FL276.1 and application thereof. In particular to bifidobacterium bifidum FL276.1 which is preserved in the China Center for Type Culture Collection on June 25, 2021, the preservation address is Wuhan University, Wuhan, Hubei province, and the preservation number is CCTCC M 2021772. The invention discloses bifidobacterium bifidum FL276.1 and application thereof, and the bifidobacterium bifidum FL276.1 can regulate intestinal flora disorder caused by ETEC infection, can reduce death rate caused by ETEC infection, effectively resists ETEC infection, and can be widely applied to preparation of freeze-dried bacterial powder, dairy products and other probiotic products.